First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

Stock Information for Senseonics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Senseonics Holdings Inc.

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist(TM) and Eversense® 365
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist(TM) and Eversense® 365
Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist(TM) Automated Insulin Delivery (AID) System
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.